Kozak, Kathryn E.
Ouyang, Linda
Derkach, Andriy
Sherman, Alexandra
McCall, Susan J.
Famulare, Christopher
Chervin, Jordan http://orcid.org/0000-0002-8596-3740
Daley, Ryan J.
Morjaria, Sejal
Mauro, Michael J. http://orcid.org/0000-0002-2251-4032
Rampal, Raajit K. http://orcid.org/0000-0002-0355-6368
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (P30 CA008748)
Article History
Received: 26 July 2021
Revised: 14 October 2021
Accepted: 18 October 2021
First Online: 5 November 2021
Competing interests
: RKR has received consulting fees from: Constellation, Novartis, Kartos, Incyte, Celgene/BMS, Promedior, CTI, Blueprint, Stemline, Galecto, Pharmaessentia, Sierra Oncology, Abbvie and research funding from Incyte, Constellation, Stemline. MJM has received consulting/advising fees from Novartis, Bristol Myers Squibb, Takeda, and Pfizer and research funding (institutional) from Novartis, Bristol Myers Squibb, and Sun Pharma/SPARC.
Free to read: This content has been made available to all.